Cargando…
The Role of Whole Body STIR MRI in Assessing First Biochemical Relapse in Patients with Myeloma
Background: Myeloma remains an incurable disease and most patients will relapse. The optimal timing of salvage initiation remains uncertain although there is a trend to treating early biochemical relapse. In the current COVID-19 pandemic, delaying therapy of asymptomatic relapsed patients is also de...
Autores principales: | Rowland, James, Mollee, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356389/ http://dx.doi.org/10.1182/blood-2020-139194 |
Ejemplares similares
-
Analysis of Sars-Cov-2-Associated Proteins Identify Tank-Binding Kinase-1 As an Immunotherapeutic Target in Multiple Myeloma
por: Ray, Arghya, et al.
Publicado: (2020) -
Sars Cov-2/COVID-19 in Multiple Myeloma Latin-American Patients COVID-Lamm Study on Behalf of Gelamm (Grupo de Estudio Latino- Americano de Mieloma Múltiple)
por: Martínez Cordero, Humberto, et al.
Publicado: (2020) -
A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts
por: Nadeem, Omar, et al.
Publicado: (2020) -
The Safety Profile of Concurrent Therapy for Multiple Myeloma in the Modern Era
por: Resende Salgado, Lucas, et al.
Publicado: (2018) -
Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)